You are here

  • Home
  • Archive
  • Volume 11, Issue 2
  • First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817

 

Online download statistics by month:

Online download statistics by month: February 2023 to July 2025

AbstractFullPdf
Feb 202312881297594
Mar 2023432434179
Apr 2023309311103
May 2023354358155
Jun 202327327380
Jul 2023317318111
Aug 202327227394
Sep 202321621889
Oct 2023203203106
Nov 2023210210108
Dec 2023180185100
Jan 202413613788
Feb 202418618797
Mar 2024187190134
Apr 2024172172123
May 2024151152109
Jun 2024153153107
Jul 202413813887
Aug 2024949367
Sep 202415615783
Oct 2024152152108
Nov 202414915079
Dec 2024165170105
Jan 2025151151103
Feb 2025290290102
Mar 2025206207119
Apr 202515815883
May 2025125124104
Jun 2025616141
Jul 2025110
Total688569233458